These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 25888716)

  • 1. Re: Cost-effectiveness of prostate cancer screening: a simulation study based on ERSPC data.
    Noordzij MA; Blanker MH
    J Natl Cancer Inst; 2015 Jun; 107(6):djv110. PubMed ID: 25888716
    [No Abstract]   [Full Text] [Related]  

  • 2. Re: Cost-Effectiveness of Prostate Cancer Screening: A Simulation Study Based on ERSPC Data.
    Taneja SS
    J Urol; 2015 Jul; 194(1):113-4. PubMed ID: 26088223
    [No Abstract]   [Full Text] [Related]  

  • 3. Response.
    Heijnsdijk EA; de Koning HJ
    J Natl Cancer Inst; 2015 Jun; 107(6):djv111. PubMed ID: 25888717
    [No Abstract]   [Full Text] [Related]  

  • 4. Cost-effectiveness of prostate cancer screening: a simulation study based on ERSPC data.
    Heijnsdijk EA; de Carvalho TM; Auvinen A; Zappa M; Nelen V; Kwiatkowski M; Villers A; Páez A; Moss SM; Tammela TL; Recker F; Denis L; Carlsson SV; Wever EM; Bangma CH; Schröder FH; Roobol MJ; Hugosson J; de Koning HJ
    J Natl Cancer Inst; 2015 Jan; 107(1):366. PubMed ID: 25505238
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness analysis of PSA-based mass screening: Evidence from a randomised controlled trial combined with register data.
    Booth N; Rissanen P; Tammela TLJ; Kujala P; Stenman UH; Taari K; Talala K; Auvinen A
    PLoS One; 2019; 14(11):e0224479. PubMed ID: 31689326
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The cost-effectiveness of prostate health index for prostate cancer detection in Chinese men.
    Teoh JY; Leung CH; Wang MH; Chiu PK; Yee CH; Ng CF; Wong MC
    Prostate Cancer Prostatic Dis; 2020 Dec; 23(4):615-621. PubMed ID: 32606435
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Re: prostate cancer screening in the randomized prostate, lung, colorectal, and ovarian cancer screening trial: mortality results after 13 years of follow-up.
    Braillon A; Dubois G
    J Natl Cancer Inst; 2012 May; 104(10):793; author reply 793-4. PubMed ID: 22491229
    [No Abstract]   [Full Text] [Related]  

  • 8. Prostate-Specific Antigen (PSA)-Based Population Screening for Prostate Cancer: An Economic Analysis.
    Tawfik A
    Ont Health Technol Assess Ser; 2015; 15(11):1-37. PubMed ID: 26366237
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Screening for prostate cancer: time to put all the data on the table.
    Haines IE; Ablin RJ; Miklos GL
    BMJ; 2016 May; 353():i2574. PubMed ID: 27226459
    [No Abstract]   [Full Text] [Related]  

  • 10. Further evidence that prostate-specific antigen screening reduces prostate cancer mortality.
    Stampfer MJ; Jahn JL; Gann PH
    J Natl Cancer Inst; 2014 Mar; 106(3):dju026. PubMed ID: 24610908
    [No Abstract]   [Full Text] [Related]  

  • 11. Correlation between stage shift and differences in mortality in the European Randomised study of Screening for Prostate Cancer (ERSPC).
    Bokhorst LP; Zappa M; Carlsson SV; Kwiatkowski M; Denis L; Paez A; Hugosson J; Moss S; Auvinen A; Roobol MJ
    BJU Int; 2016 Nov; 118(5):677-680. PubMed ID: 27104278
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Prostate cancer screening benefit very low, even after 13 years].
    Blanker MH; Noordzij MA
    Ned Tijdschr Geneeskd; 2014; 158():A8349. PubMed ID: 25492737
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Is prostate cancer screening cost-effective? A microsimulation model of prostate-specific antigen-based screening for British Columbia, Canada.
    Pataky R; Gulati R; Etzioni R; Black P; Chi KN; Coldman AJ; Pickles T; Tyldesley S; Peacock S
    Int J Cancer; 2014 Aug; 135(4):939-47. PubMed ID: 24443367
    [TBL] [Abstract][Full Text] [Related]  

  • 14. RE: Prostate-specific antigen screening trials and prostate cancer deaths: the androgen deprivation connection.
    Carlsson S; Roobol MJ; Schröder FH; Hugosson J; Auvinen A
    J Natl Cancer Inst; 2014 Apr; 106(5):. PubMed ID: 24771874
    [No Abstract]   [Full Text] [Related]  

  • 15. Re: Prostate-specific antigen screening trials and prostate cancer deaths: the androgen deprivation connection.
    Walsh PC
    J Natl Cancer Inst; 2014 Feb; 106(2):djt432. PubMed ID: 24399847
    [No Abstract]   [Full Text] [Related]  

  • 16. Re: The added value of percentage of free to total prostate-specific antigen, PCA3, and a kallikrein panel to the ERSPC risk calculator for prostate cancer in prescreened men.
    Taneja SS
    J Urol; 2015 Jan; 193(1):127. PubMed ID: 25523657
    [No Abstract]   [Full Text] [Related]  

  • 17. Response.
    Stattin P; Carlsson S; Jonsson H
    J Natl Cancer Inst; 2014 Oct; 106(10):. PubMed ID: 25269489
    [No Abstract]   [Full Text] [Related]  

  • 18. American Urological Association (AUA) guideline on prostate cancer detection: process and rationale.
    Carter HB
    BJU Int; 2013 Sep; 112(5):543-7. PubMed ID: 23924423
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Re: prostate cancer mortality in areas with high and low prostate cancer incidence.
    Pinsky PF
    J Natl Cancer Inst; 2014 Oct; 106(10):. PubMed ID: 25269488
    [No Abstract]   [Full Text] [Related]  

  • 20. Re: Public knowledge of benefits of breast and prostate cancer screening in Europe.
    Brenner H; Heywang-Köbrunner S; Becker N
    J Natl Cancer Inst; 2010 Mar; 102(5):356; author reply 356-7. PubMed ID: 20075365
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.